Immunomodulation and Biomaterials

References

• Keane V F, Maddy MF. Host defenses and infectious complications in maintenance hemodialysis patients. In Replacement of renal function by dialysisThird Ed, JF Maher, 1988; 865–880
   Google Scholar
• Brunner F P, Broyer M, Brynger H, Challah S, Fassbinder V, Oules R, Rizzoni G, Selwood N H, Wing AJ. Combined report on regular dialysis and transplantation in Europe, XV 1984. Proc Eur Dial Transpl Ass 1985; 22: 5–54
   Google Scholar
• Santiago A, Chazan JA. Factors associated with mortality among 405 chronic hemodialysis patients who died bettween 1973 and 1985. Kidney Int 1987; 31: 245
   Google Scholar
• Kohler H, Arnold W, Renshin G, Dormeyer H H, Meyer Zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124–128
   PubMed Web of Science ®Google Scholar
• Stevens C E, Alter M D, Taylor P E, Zang E A, Harley E J, Sztiuness V. Hepatitis B vaccine in patients received hemodialysis. Immunogenecity and efficacy. N Engl J Med 1984; 311: 496–500
   PubMed Web of Science ®Google Scholar
• Morrison A B, Maness K, Tawes R. Skin homograft survival in chronic renal insufficiency. Arch Pathol 1963; 75: 139–143
   Google Scholar
• Kirkpatrick C H, Wilson W EC, Talmage DW. Immunologic studies in human organ transplantation. I. Observation and characterization of suppresed cutaneous reactivity in uremia. J Exp Med 1964; 119: 727–742
   PubMed Web of Science ®Google Scholar
• Lindner A, Farewell V T, Sherrard DJ. High incidence of neoplasia in uremic patients receiving long-term dialysis. Nephron 1981; 27: 292–296
   PubMed Web of Science ®Google Scholar
• Jacobs C, Brunner F P, Brynger H, Chantler C, Donckerwolcke R A, Hathway R A, Kramer P, Selwood N H, Ving AJ. Malignant diseases in patients treated by dialysis and transplantation in Europe. Transpl Proc 1981; 13: 729–732
   PubMed Web of Science ®Google Scholar
• Langhoff E, Ladefoged J. Cellular immunity in renal failure: depression of lymphocyte trasformation by uremia and methylprednisolone. Intra-individual consistency of lymphocyte responses to the in vitro suppressive effect of steroid. Int Arch Allergy Appl Immunol 1984; 74: 241–245
   Google Scholar
• Raskova J, Ghobrial I, Shea S M, Ebert E C, Eisinger R P, Raska K, Jr. T Cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity and interleukin 2 production and receptor generation. Diagnostic Immunol 1986; 4: 209–216
   PubMedGoogle Scholar
• Meuer S C, Hauer M, Kurz P, Meyer Zum Buschenfelde K H, Kohler H. Selective blockade of the antigen receptor mediated pathway of T Cell activation in patients with impaired primary immune responses. J Clin Invest 1987; 80: 743–749
   PubMed Web of Science ®Google Scholar
• Kurz P, Kohler H, Meuer S C, Hutteroth T H, Meyer Zum Buschenfelde KH. Impaired cellular immune responses in chronic renal failure: evidence for T cell defect. Kidney Int 1986; 29: 1209–1214
   PubMedGoogle Scholar
• Tsakolos N D, Theoharides T C, Hendler E D, Goffinet J, Dwyer J M, Vhisler R L, Askenase PV. Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis. Clin Exp Immunol 1986; 63: 218–227
   PubMed Web of Science ®Google Scholar
• Kleiman KB, Zoschke DC. Suppression of human lymphocyte responses in chronic renal failure mediated by adherent cells: analysis of serum-free media. J Lab Clin Med 1985; 106: 262–268
   Google Scholar
• Raskova J, Raska K. Humoral inhibitor of the immune response in uremia. V. induction of suppressor cells in vitro by uremic serurm. Am J Pathol 1983; 111: 149–155
   Google Scholar
• Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, Galanaud P, Bach J F, Delfraissy JF. Presence of preactivated T cells in hemodialyzed patients: their possible role in alterd immunity. Proc Natl Acad Sci USA 1986; 83: 7457–7461
   PubMed Web of Science ®Google Scholar
• Langhoff E, Hofman B, Odum N, Ladefoged J, Platz P, Ryder L P, Svejgaard A. Kinetic analysis of interleukin-2 (IL-2) production and expression o IL-2 receptors by uremic and normal lymphocytes. Scand J Immunol 1987; 25: 29–36
   PubMedGoogle Scholar
• Kurland J I, Beckmann R. Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med 1978; 147: 941–957
   Google Scholar
• Chouaib S, Welk K, Mertelsmann R, Dupont B. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation. Inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol 1985; 135: 1172–1179
   PubMed Web of Science ®Google Scholar
• Rappaport R S, Dodge GR. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med 1982; 155: 943–948
   PubMed Web of Science ®Google Scholar
• Tchorzewski H, Luciak M, Tranadel K, Majenska E, Pokoca L. Effect of HD on T lymphocytes subsets, con-A activated suppressor cell activity and interleukin-2 receptor expression on lymphocytes in chronic uremic patients. Art Organs 1989; 13: 185–189
   PubMed Web of Science ®Google Scholar
• Kazatchkine M D, Haeffner-Cavaillon N. Mechanisms and consequences of complement activation during hemodialysis. Adv Exp Med Biol 1989; 260P: 19–26
   Google Scholar
• Bligaard N, Renviq L. Dialysis membranes interference in human T lymphocytes proliferation assays. APMIS 1989; 97: 361–366
   Google Scholar
• Luger A, Kovarik J, Stummvoll H K, Urbanska A, Luger TA. Blood membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987; 32: 84–88
   PubMed Web of Science ®Google Scholar
• Kay N E, Raij L. Differential effect of hemodialysis membranes on human lymphocyte natural killer function. Art Organs 1987; 11: 165–167
   PubMed Web of Science ®Google Scholar
• Lewis S L, Van Epps D E, Chenoweth DE. Density changes in leukocytes following hemodialysis or exposure to chemotactic factor. Am J Nephrol 1986; 6: 34–41
   Google Scholar
• Hakim R M, Fearon D T, Lazarus JM. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1934; 26: 19–1200
   Google Scholar
• Huttunen K, Lampainen E, Silvennoinen-Kassinen S, Tiilikainen A. The neutrophil function of uremic patients treated by hemodialysis or CAPD. Scand J Urol Nephrol 1984; 18: 167–172
   PubMed Web of Science ®Google Scholar
• Mion C, Canaud B, Stec F, Nguyen QV. Dialysat au bicarbonate sterile et sans pyrogene: un progres en hemodialyse applicable des aujourd'hui. Actual Nephrol 1989; 22: 286–326
   Google Scholar
• Tetta C, Segoloni G, Mariano F, Montrucchio G, Turello E, Camussi G. Leukocyte-derived mediators and biocompatibility. Nephrol Dial Transpl 1990, in press
   Google Scholar
• Beaurain G., Naret C, Marcon L, Grateau G, Drueke T, Urena P, Nelson DL, Bach JF, Chatenoud L. In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 1989; 36: 636–644
   PubMed Web of Science ®Google Scholar
• Old LJ. Tumor necrosis factor: polypeptide mediator network. Nature 1987; 326: 330–331
   PubMed Web of Science ®Google Scholar
• Herbelin A, Nguyen A T, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 1990; 37: 116–125
   PubMed Web of Science ®Google Scholar
• Camussi G, Tetta C, Montrucchio G, Turello E, Vercellone A. Immunopathology and progression of experimental renal disease. Contr Nephrol 1989; 75: 1–12
   Google Scholar
• Beutler B, Cerami A. Cachectin: more than a tumour necrosis factor. New Eng J Med 1987; 316: 379–385
   PubMed Web of Science ®Google Scholar
• Camussi G, Tetta C, Bussolino F, Turello E, Brentjens J, Montrucchio G, Andres G. The effect of leukocyte stimulation on rabbit immune complex glomerulonephritis. Kidney Int 1990, in press
   Google Scholar
• Baud L J, Oudinet J P, Bens M., Noel L, Peraldi MN, Etienne J, Ardaillou R. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 1989; 35: 1111–1118
   PubMed Web of Science ®Google Scholar
• Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987; 166: 1390–1404
   PubMed Web of Science ®Google Scholar
• Salem P, Devyck Dulioust A, Vivier E, Denizot Y, Damais C., Dinarello CA, Thomas Y. Immunoregulatory functions of paf-acether. IV. Enhancement of IL-1 production by muramyl-dipeptide-stimulated monocytes. J Immunol 1990; 144: 1338–1344
   PubMed Web of Science ®Google Scholar
• Le J, Vilcek K. Biology of disease. Tumor Necrosis Factor and Interleukin-1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234–248
   PubMed Web of Science ®Google Scholar
• Beutler B, Milsark I V, Cerami A. Passive immunization against cachectin/tumour necrosis factor protects mice from lethal effect of endotoxin. Science (Wash. DC) 1985; 29: 869–871
   Google Scholar
• Vaage A, Espevik T, Halsteusen A. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355–357
   Google Scholar
• Mathison J C, Volfson E, Ulevitch D. Partecipation of tumor necrosis factor in the mediation of Gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925–1937
   PubMed Web of Science ®Google Scholar
• Port F K, VanDerKerkhove K, Kunkel S L, Kluger MJ. The role of dialysate in the stimulation of IL-1 production during clinical hemodialysis. Am J Kidney Dis 1987; 10: 118–122
   PubMed Web of Science ®Google Scholar
• Blumenstein M, Schmidt B, Vard R A, Ziegler-Heitbrock H W, Gurland H J. Altered interleukin-1 modulation in patients undergoing hemodialysis. Nephron 1988; 50: 277–281
   Google Scholar
• Bingel M, Lonnemann G, Koch K M, Dinarello C A, Shaldon S. Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes. Nephron 1988; 50: 273–276
   PubMedGoogle Scholar
• Haeffner-Cavaillon N, Cavaillon J M, Ciancioni C, Bade F, Delon S, Kazatchkine MD. In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989; 35: 1212–1218
   PubMed Web of Science ®Google Scholar
• Laude M, Haeffner-Cavaillon N, Pusineri C, Bade F, Poignet J L, Delon S, Kazatchkine MD. Induction of Interleukin-1 production during hemodialysis with non-complement activating high-permeability membranes. Lymphokine Res 1988; 7: 335, Abs
   Google Scholar
• Schindler R, Lonnemann G, Shaldon S, Koch K M, Dinarello CA. Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990; 37: 85–93
   PubMed Web of Science ®Google Scholar
• Tetta C, Camussi G, Turello E, Salomone M, Priolo G, Aimo G, Segoloni G, Vercellone A. The production of cytokines in hemodialysis. Blood Purif 1990, in press
   Google Scholar
• Leber H W, Vizemann V, Goubeaud G, Rawer P, Schutterle G. Simultaneous hemofiltration/hemodialysis: an effective alternative to hemofiltratlon and conventional hemodialysis in the treatment of uremic patients. Clin Nephrol 1978; 9: 115–121
   Google Scholar